Research

I am currently Chairman of the International Breast Cancer Intervention Study (IBIS) Steering Group and the ATAC trial. I have worked extensively in breast cancer and was the first to report the effect of tamoxifen on contralateral tumours as an indicator of its potential chemopreventive role. I demonstrated that a change in mammographic breast density on endocrine treatment is a biomarker for its effectiveness.

I am involved in studies on the use of HPV assays for cervical screening, the use of flexible sigmoidoscopy for colorectal cancer screening and markers for the behaviour of early prostate cancer.

I am the statistician for several major breast cancer trials and maintain an active interest in developing new statistical methodology, especially in the area of adjustments for non-compliance and cross-over, and multi-arm clinical trials.

Other Activities

• Fellow of the Academy of Medical Sciences
• Fellow of the Royal Society
• Science Strategy Committee member for Breast Cancer Now
• Research Strategy Group member for Prostate Cancer UK

Major Funding

• 2018-2023- CRUK, Catalyst, £1.4M
• 2017-2020- Barts Charity, Preventative Neurology, £1.5M
• 2014-2019- CRUK, Cancer Prevention, £6.9M
• 2007-2019- CRUK, IBIS II, £2M

Recent Publications

Methylation of HPV 16 and EPB41L3 in oral gargles: Associations with oropharyngeal cancer detection and tumor characteristics Giuliano AR, Nedjai B, Lorincz AT et al. International Journal of Cancer (2020) 146(7) 1018-1030

Validation of the OncoMASTR risk score in estrogen receptor–positive/HER2-negative patients: A TransATAC study Buus R, Sestak I, Barron S et al. Clinical Cancer Research (2020) 26(7) 623-631

Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Cuzick J, Sestak I, Forbes JF et al. Lancet (2020) 395(2) 117-122
https://www.ncbi.nlm.nih.gov/pubmed/31839281

Ethnic and Socioeconomic Associations with Multiple Sclerosis Risk Dobson R, Jitlal M, Marshall CR et al. Annals of Neurology (2020) (7)

Measurement challenge: Protocol for international case-control comparison of mammographic measures that predict breast cancer risk Dench E, Bond-Smith D, Darcey E et al. BMJ Open (2019) 9(7)

Impact of screening on cervical cancer incidence: A population-based case-control study in the United States. Landy R, Sasieni PD, Mathews C et al. Int J Cancer (2019) (2)
https://www.ncbi.nlm.nih.gov/pubmed/31837006

Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool. Phillips K-A, Liao Y, Milne RL et al. JNCI Cancer Spectr (2019) 3(2) pkz066
https://www.ncbi.nlm.nih.gov/pubmed/31853515

European Guidelines on the Organisation of Breast Centres and Voluntary Certification Processes. Biganzoli L, Marotti L, Cardoso M-J et al. Breast Care (2019) 14(1) 359-365
https://www.ncbi.nlm.nih.gov/pubmed/31933581

The Parkinson's Disease Mendelian Randomization Research Portal Noyce AJ, Bandres-Ciga S, Kim J et al. Movement Disorders (2019) 34(7) 1864-1872

Relationships of p16 Immunohistochemistry and Other Biomarkers With Diagnoses of Cervical Abnormalities: Implications for LAST Terminology. Castle PE, Adcock R, Cuzick J et al. Arch Pathol Lab Med (2019) (2)
https://www.ncbi.nlm.nih.gov/pubmed/31718233

Biography

I received my BSc in Mathematics and Physics from Harvey Mudd College, Claremont, California. I then studied an MSc in Mathematics at the University of London. I obtained my PhD in Mathematics from Claremont Graduate School, Claremont, California.

I was appointed John Snow Professor of Epidemiology at Queen Mary University of London. In 2017, I was awarded a CRUK Lifetime Achievement Award and a CBE.